IBC’s 3rd European Protein Kinase Targets, Amsterdam, The Netherlands
Event Nov 03
Protein Kinases are the second largest group of drug targets, after GPCRs, and account for 20-30% of the drug discovery programmes of many companies. With several protein kinase inhibitors already approved for clinical use (Gleever, Iressa, Fasudil) and many more undergoing human clinical trials, kinases offer an exciting therapeutic potential to target serious disease groups, including Cancer, Neurodegenerative and Metabolic diseases.
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018